Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats.

摘要: Extended-release buprenorphine is an effective analgesic in laboratory animals, and its safety has been established mice but not rats. The authors used a target animal trial to evaluate the of extended-release Fischer 344 rats received post-surgical subcutaneous injections 1.3 mg, 3.9 mg or 6.5 per kg body weight (two times, six times ten intended dose, respectively), their weight, clinical signs symptoms, pathology histopathology were monitored for 4 d. Body was significantly different that compared with control Signs nausea-related behavior observed 25% treated buprenorphine. Clinical results all normal, gross microscopic examinations identified no substantial abnormalities, suggesting this minor consequence. Other adverse events previously reported occur opiate therapy, including loss dermal lesions at drug injection sites, study. study show administration product safe does necessarily cause effects, confirming therapy viable choice medicine.